Highlights the risk of spontaneous intracranial hemorrhage, specifically subdural hematoma, associated with newer P2Y12 inhibitors like ticagrelor.
Answers are grounded in this paper and cite their sources.
Supports risk stratification to minimize ICH with antiplatelet therapy in ACS; leaves optimal strategies open pending higher-level evidence.
Antiplatelet therapy has established clinical benefit on cardiovascular outcome and has reduced the rates of re-infarction/in stent thrombosis following percutaneous coronary intervention in acute coronary syndromes. Major bleeding episodes can occur with antiplatelet therapy and intracranial hemorrhage (ICH) is one of the most feared complications resulting in significant morbidity and mortality. Identification of high risk groups and judicious use of antiplatelet therapy reduces the bleeding risk. Ticagrelor is a newer P2Y12 receptor antagonist with established clinical benefit. However, risks of having an ICH with these newer molecules cannot be ignored. Here, we report a case of spontaneous acute subdural hematoma developing in a patient on antiplatelet therapy with aspirin and ticagrelor. Early recognition, discontinuation of the medication and appropriate management resulted in resolution of hematoma and good clinical outcome. Authors have reviewed the antithrombotic drugs and their tendencies in causing intracranial bleeds from a neurophysicians perspective.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: